Astellas PharmaALPMF -2.73%73 Interest Coverage is 16.00 as of Mar. 2026, which is 62% below its 10-year median of 42.54. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.18 (Fairly Valued). The stock has 4 warning signs investors should review. Among 685 Drug Manufacturers companies, Astellas Pharma ranks better than 63.8% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Astellas Pharma's
Operating Income
for the
three
months ended in Mar. 2026 was $306 Mil. Astellas Pharma's Interest Expense for the
three
months ended in Mar. 2026 was $-19 Mil.
Astellas Pharma's interest coverage for the quarter that ended in Mar. 2026 was 16.00.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Astellas Pharma's Interest Coverage or its related term are showing as below:
ALPMF'
s Interest Coverage Range Over the Past 10 Years
Min: 1.58 Med: 42.54 Max: 188.59
Current: 27.01
ALPMF's Interest Coverage is ranked better than 63.8% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs ALPMF: 27.01
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Astellas Pharma Interest Coverage Related Terms
Astellas Pharma Interest Coverage Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ALPMF vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (ALPMF) has a Interest Coverage of 16.00 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Astellas Pharma and its competitors. This is 62% below median its historical median of 42.54. Over the past decade, Astellas Pharma's Interest Coverage has ranged from 1.58 to 188.59. According to the industry distribution chart, Astellas Pharma ranks #248 out of 685 companies in the Drug Manufacturers industry, placing it in the top 36.2%.
Is Astellas Pharma's Interest Coverage too high?
Astellas Pharma's current Interest Coverage of 16.00 is 62% below median its 10-year median of 42.54. Over the past 10 years, this metric has ranged from a low of 1.58 to a high of 188.59. The Drug Manufacturers industry median Interest Coverage is 12.78. Astellas Pharma's value of 16.00 is 25.2% above this industry median. Based on the distribution chart, Astellas Pharma ranks #248 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #248 out of 685 companies for Interest Coverage. This puts Astellas Pharma in the upper half of its industry. The industry median Interest Coverage is 12.78. Astellas Pharma's value of 16.00 is 25.2% above this benchmark. Historically, Astellas Pharma's own Interest Coverage has ranged from 1.58 to 188.59 over the past decade. While the company's 10-year median is 42.54 vs. the industry median of 12.78, Astellas Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current Interest Coverage of 16.00 is 25.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current Interest Coverage is 16.00, which is 62% below median its own 10-year median of 42.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.18, compared to a current price of $12.85 — trading 9.4% below its estimated fair value. The current Interest Coverage is 16.00, which is 62% below median its 10-year median of 42.54 and 25.2% above the Drug Manufacturers industry median of 12.78. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Interest Coverage is 16.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $12.85 is trading 9.4% below its estimated GF Value™ of $14.18.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
Interest Coverage: 16.00 (62% below median its 10-year median of 42.54)
GF Value™: $14.18 vs. price of $12.85 (9.4% below fair value)
Industry Position: 25.2% above the Drug Manufacturers median (#248 of 685)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
